Skip to Content

UBM Medica's CancerNetwork Provides Key Coverage of the 2011 ASH Meeting in San Diego

NORWALK, Conn., Dec. 15, 2011 /PRNewswire/ -- UBM Medica's CancerNetwork, a leading website for oncology news, reviews, and perspectives, is showcasing extensive and carefully selected coverage of this past week's 2011 American Society of Hematology (ASH) meeting in San Diego, California, the largest annual meeting for practicing hematologists in the U.S.

(Photo: )

Key reports by CancerNetwork editors on several pivotal trial results revealed at the conference include:

Results on the treatment of Splenic Marginal Zone Lymphoma with rituximab monotherapy
Phase 2 results on the use of Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic ALCL
Phase 3 data showing that fractionated doses of gemtuzumab ozogamicin combined with standard chemotherapy improves survival in AML patients aged 50-70.
Results from the SAVE-ONCO trial of semuloparin in cancer patients to prevent VTE
Other noteworthy advances reported in the treatment of hematologic malignancies include:

Two sources of adult stem cells from unrelated donors show no differences in transplant outcomes
Gemtuzumab: A potential new use  for an old drug in acute myeloid leukemia
In addition to articles distilling the news from ASH, CancerNetwork features an exclusive podcast with Andrew Evens, DO, MSc, from UMass Medical School, discussing a retrospective study of women diagnosed with lymphoma. In the interview, Dr. Evens stresses that one of the reasons for performing the study was the relative rarity of the disease, saying that "when it's a rare entity, there's not as much published data in the literature to guide us even as specialists, much less for physicians out in the community."

"Our service to our readers has always been to selectively cover large oncology meetings to ensure that we report only on the news that will change the way oncologists—both in the academic and community setting—practice day to day," said Rachel Warren, Editorial Director for ONCOLOGY and CancerNetwork.

About UBM Medica


Addressing today's healthcare information needs, UBM Medica, a division of UBM plc (UBM.L), delivers strategic, integrated communications solutions and comprehensive reach—online, in print, live, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, drug databases, data services, live events, and other valuable resources, UBM Medica also delivers comprehensive communication solutions for the pharmaceutical and related industries. US websites include,,,,, and  Employing more than 1,400 people with offices in 29 countries, UBM Medica is headquartered in London.  For more information, visit


Media contact:

Amy Erdman
Marketing Director






Web Site:


Posted: December 2011